$ALHC

Maroney Dawn Christine sold $586K of ALHC

Maroney Dawn Christine (President) sold 30,000 shares of Alignment Healthcare, Inc. (ALHC) at $19.55 ($0.59M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maroney Dawn Christine
Published Jun 15, 2026, 11:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 11:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
medium confidence
Mentioned
$ALHC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The newest disclosed fact is the officer’s open-market sale of 30,000 shares at a stated price, with holdings after the transaction and confirmation of a pre-arranged 10b5-1 plan.

02

Market read

Provides a concrete, same-day insider sale datapoint that can influence short-term sentiment, though 10b5-1 reduces interpretive weight.

03

What to watch

Traders may over-weight insider sales; the key incremental information here is the exact share count, price, and that the plan is pre-arranged.

Relevance 4/10Novelty 6/10Timing: SEC Form 4 filed on 2026-06-15 (transaction dated 2026-06-15)

Background

The article is an SEC Form 4 insider transaction disclosure for Alignment Healthcare, Inc. (ALHC).

Company-level read

Ticker impact

$ALHCNeutralMedium confidence
Context

Alignment Healthcare President Maroney Dawn Christine sold 30,000 shares in an open-market transaction at $19.5475 on 2026-06-15 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be muted given the 10b5-1 pre-arranged nature.

Evidence & confidence

The filing provides a concrete transaction size and price, but the presence of a pre-arranged 10b5-1 plan typically lowers interpretive value versus discretionary selling.

Market effects

No sector-level read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • Alignment Healthcare, Inc.

    Subject of the Form 4 insider transaction disclosure (ALHC).

  • Maroney Dawn Christine

    President and reporting officer who sold 30,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMed

Why Alignment Healthcare (ALHC) Stock Is Up Today

Alignment Healthcare (ALHC) shares rose 8.6% after its subsidiary announced a new Medicare Advantage plan in Los Angeles and Orange counties. Analyst Ryan Langston lowered his price target to $12 but maintained a Buy rating, citing inpatient utilization pressure. The stock had fallen 13.4% the previous day due to a downgrade and regulatory concerns.

$HUMMedAI 8/10

Humana Rebounds in Medicare Advantage Star Ratings for 2027

Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.

$ALHCHigh

ALHC Stock Slides As Legal, Cost, And Rating Pressures Mount

Alignment Healthcare Inc. (ALHC) stock fell 14.75% on October 9, 2026, amid concerns over Medicare Advantage reimbursement pressures, legal issues, and cost challenges. The company reported $1.34B in revenue and $36.6M in net income for the latest quarter, but negative cash flow raised concerns. CMS's 2027 Star Ratings and a whistleblower's accounting allegations further pressured the stock, with Barclays cutting its price target to $10.